NuSep licences gels

By Dylan Bushell-Embling
Wednesday, 17 September, 2008

NuSep [ASX: NSP] will accept an offer to license its electrophoresis gel business.

The third party had offered to acquire NuSep's gels business outright or to license the technology.

It was decided that licensing the technology would provide the best return for shareholders, the company said.

The licensing deal should give NuSep enough money to fund this commercialisation of its MF10 and SpermSep separation instruments without any additional fund-raising, and will likely generate an ongoing royalty fee.

NuSep also supplies research grade biological products such as human IgG and albumin.

Related News

Hormone therapy shifts body proteins to match gender identity

Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...

Targeting 'molecular bodyguards' weakens prostate cancer cells

Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...

Females found to carry a higher genetic risk of depression

An international team of scientists has discovered about twice as many genetic 'flags'...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd